4D Molecular Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good afternoon, everyone. Thank you for joining us today. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have with us today live in London at the Jefferies Global Healthcare Conference, the management team of FDMT, 4D Molecular Therapeutics. Just to kick us off, David's going to start with a few slides, and then we'll go into Q&A after that. David, let me pass to you.
Fantastic. Thanks for having us. All right. We're going to dive right in here. Typical legal disclaimer. Okay, so today we're going to be focused on our lead asset, 4D-150, which we think has the potential to create a new treatment paradigm in wet AMD and other neovascular diseases. I've got four key takeaways for you today. Number one is with a single intravitreal injection, routine in-clinic injection into the vitreous, we believe this will result in a continuous backbone treatment for patients throughout the rest of their life. That means this disease that's waxing and waning, but always on, will be treated with a disease treatment that's always on. Number two, we think that 4D-150 has the potential to address the two highest unmet needs in wet AMD, and that is treatment burden. It's very, very high. We want to bring that down and also maintain vision over time.
Number three, we believe our phase II clinical results and our phase III design has really set us up for success, together with our excellent execution in terms of enrollment. Finally, number four, you'll hear from Chris today, we believe 4D-150 has huge commercial potential based on our interactions and interviews with payers, physicians, and patients. Okay, so to remind you, 4D-150 has a proprietary capsid that we invented through a Nobel Prize-winning technology called directed evolution. This allows us to use an intravitreal injection instead of subretinal at a very low dose and low inflammatory risk, and still transduce the retina broadly. Our payload is aflibercept plus a VEGF-C RNAi, so we have the potential to treat, hit four different molecular targets here.
Again, the primary mechanism of action here is the aflibercept, which has been in over 60 million eyes safely and effectively. So, we're expressing a very well-validated biologic and market leader. On the top, what you can see is a representation of the disease activity in wet AMD. These patients have this disease for the rest of their life after diagnosis. It waxes and wanes in terms of intensity, but it's always there. Unfortunately, the current bolus anti-VEGFs, huge market, but still under-treat the disease. What you can see is on the bottom row there, the typical treat and extend concentrations of anti-VEGF bolus therapies in the vitreous, where you get a high spike and then it's gone.
Over time, physicians try to extend patients to decrease the treatment burden, which means for large periods of time, the patient is untreated with this severe chronic disease. We believe with a continuous backbone treatment with a gene therapy expressed from the retina, we have the potential to continuously protect patients from disease activity for the rest of their life, which is a real game changer. Why is this important? Beyond just reducing treatment burden, which will have a huge impact on quality of life, there is also the potential to maintain vision. To remind you, as you can see in the dashed line, with real-world data on bolus anti-VEGF therapeutics, patients lose vision. Despite these being potent biologics, they lose vision. We believe with a continuous backbone therapy, we can maintain vision for the rest of the patient's life.
This is data from our two-year results from a recently diagnosed population, so as close as we have to phase III population. You can see over two years, a nice control of the central subfield thickness on the top, and also maintenance of best corrected visual acuity over two years, which is very important. Also important on the right is you see a treatment burden reduction estimate for these patients being close to 90% treatment burden reduction. That is a real game changer for these patients. Roughly two-thirds were still free of the need for any supplemental bolus injections at two years. Safety is critical in a large disease like this. We are pioneers in terms of bringing gene therapy to a large market.
You can see here in green, this shows you the percentage of patients at each time point who are free of inflammation. You can see from six months on, 100% are free of inflammation. During the first six months, we have a couple of patients who had mild inflammation, which was easily controlled with topical steroid eye drops. Importantly, no significant serious adverse events or vision-threatening complications were described. To reiterate, 4D-150 is really designed to be a potential backbone therapy for continuous disease control. Again, we believe this will be lifelong, will preserve vision, reduce treatment burden. Again, we believe the safety profile today has been very predictable and favorable. This is all achieved with a single intravitreal injection in the clinic.
Briefly, our 4FRONT-1 and 4FRONT-2 phase III trials are both North America and global, both very well powered with roughly 520 to 530 patients on each. We have strong regulatory alignment globally. The patient population here has been optimized based on what we saw in phase II. We exclude patients with extreme CST. Those outliers are excluded, and then we also require a response to aflibercept on study to make sure these are highly responsive patients. The other issue that is very important in these sort of non-inferiority studies for BCVA is what are the supplemental injection criteria that patients can receive to protect their BCVA? Here we have got a broad range of criteria that will help to protect the BCVA. Patients, if they get too severe progression on CST, they will be rescued. On vision alone, they will be rescued.
And then also with the combination of five letters and 50 microns, they will also be rescued. We think these are strong criteria that will protect the primary endpoint of BCVA in the study, and still give us a large treatment burden reduction. 2026 has been a busy year for us. You can see broad progress across wet AMD, DME, and at the company level. Our main upcoming readouts are Q2 2027 will be the 4FRONT-1 phase III, and the second half of 2027 for the 4FRONT-2 readout. Very important upcoming data releases coming, and we are in a strong cash position. Those are our introductory comments.
Thank you. Awesome. Thank you, David.
We can get into some Q&A now. Yeah, feel free to join me here. One thing I want to just understand is that within wet AMD, I think you laid out nicely that there is sort of this perpetual need for treatment, and what you are essentially measuring in the disease in addition to anatomy is, how burdensome is the treatment? Which, if you kind of take a step back, it is kind of a wild concept. Your goal is to really create a step change in that. Could you help quantify for us? Obviously, the data that you just ran us through, it is amazing. It is paradigm-shifting. But what level do you need to see in phase III to kind of continue to bolster that, right? Because the bar set by your phase II data is sky-high.
Yeah. Where do you need to land to feel good about your phase III?
Sure. Why don't we start with Chris Simms, our Chief Commercial Officer? He can weigh in on kind of what we have seen with prior products and what we expect to see here.
Yeah, happy to. Thanks for the opportunity to be here. Maybe a quick walk down history lane, really quick. anti-VEGF has been injected in the eye for 20 years, right, since the introduction of Lucentis. Large market, approximately $16 billion globally. Markets continue to grow every year, and there's been innovation. What's been interesting is that every new agent that's come to market, everything has been in the pursuit of durability. When you think of it from a patient's perspective, needles in your eye every four, six, eight, 12 weeks, if you can reduce that, obviously that's of immense value. But everything that's come to market, you look at Vabysmo and Eylea HD compared to what standard of care was, the incremental benefit as measured by a percentage of treatment burden reduction is about 20%, right?
If we looked at real-world data recently, we went back to 2021 for a five-year look back, and that's in the period where longer-acting agents like Vabysmo have come to market, and the average real-world increase in durability has been about 10 days. So there's been a delta, for sure, but largely incremental. Despite that incremental benefit, these medicines have become multi-blockbusters. Vabysmo, I think, lately is on track to be a $4 billion-$5 billion drug for Roche, with the benefit of about two weeks of incremental durability. I share that history lesson just to give you context as to what will be meaningful here. Well, meaningful in the past with these bolus therapies has been about 20%. We're seeing results through our phase II program in the 80%-90% range by comparison.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
